Advances and challenges in biomarker development for type 1 diabetes prediction and prevention using "omic" technologies

Expert Opinion on Medical Diagnostics

Volumn 4, Issue 5, 2010, Pages 397-410

  Carey, Colleen ^a   Purohit, Sharad ^a   She, Jin Xiong ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Biomarkers; Prediction; Prevention; Type 1 diabetes

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN;

ANALYTIC METHOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE MAPPING; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVENTION; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; TRANSCRIPTOMICS; VALIDATION PROCESS;

EID: 77955600908     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2010.508492     Document Type: Review

References (137)

1. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2009;9(5):A355-65
2. Bruno G, Novelli G, Panero F, et al. The incidence of type 1 diabetes is increasing in both children and young adults in Northern Italy: 1984-2004 temporal trends. Diabetologia 2009;52(12):2531-2535
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301(20):2129-2140
4. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart 2008;94(11):1376-1382
5. Atkinson MA. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why cant we prevent or reverse this disease? Diabetes 2005;54(5):1253-1263
6. Bingley PJ, Bonifacio E, Williams AJ, et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46(11):1701-1710
7. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995;38(7):816-822
8. Jin Y, Chen X, Podolsky R, et al. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin Immunol 2009;130(3):272-279
9. Hedman M, Faresjo M, Axelsson S, et al. Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children. Clin Exp Immunol 2008;153(3):360-368
10. Chen X, Makala LH, Jin Y, et al. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood. Clin Immunol 2008;129(3):413-418
11. Hinkmann C, Knerr I, Hahn EG, et al. Reduced frequency of peripheral plasmacytoid dendritic cells in type 1 diabetes. Horm Metab Res 2008;40(11):767-771 (Pubitemid 352772689)
12. Driver JP, Scheuplein F, Chen YG, et al. Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes 2010;59(2):423-432
13. Eisenbarth GS, Kotzin BL. Enumerating autoreactive T cells in peripheral blood: a big step in diabetes prediction. J Clin Invest 2003;111(2):179-181
14. Noble JA, Valdes AM, Cook M, et al. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996;59(5):1134-1148
15. Franke A, Hampe J, Rosenstiel P, et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS ONE 2007;2(1):e691
16. Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008;40(10):1211-1215
17. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008;40(12):1402-1403
18. Comabella M, Craig DW, Camina-Tato M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS ONE 2008;3(10):e3490
19. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316(5829):1331-1336
20. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445(7130):881-885
21. Timpson NJ, Lindgren CM, Weedon MN, et al. Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. Diabetes 2009;58(2):505-510
22. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40(5):638-645
23. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven commo diseases and 3,000 shared controls. Nature 2007;447(7145):661-678
24. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009
25. Grant SF, Qu HQ, Bradfield JP, et al Follow-up analysis of genome-wide association data identifies novel loci fo type 1 diabetes. Diabetes 2009;58(1):290-295
26. Grant SF, Hakonarson H. Genome-w association studies in type 1 diabetes. Curr Diab Rep 2009;9(2):157-163
27. Hakonarson H, Qu HQ, Bradfield JP et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identifie by a genome-wide association study. Diabetes 2008;57(4):1143-1146
28. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38(6):617-619
29. Cooper JD, Smyth DJ, Smiles AM, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008;40(12):1399-1401
30. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wi analyses of type 1 diabetes. Nat Genet 2007;39(7):857-864
31. GWAS Catalog. Available from: www.genome.gov/gwastudies [Last accessed July 9 2010]
32. Fung EY, Smyth DJ, Howson JM, et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility loc Genes Immun 2009;10(2):188-191
33. Todd JA. Statistical false positive or true disease pathway? Nat Genet 2006;38(7):731-733
34. Concannon P, Chen WM, Julier C, et al. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 2009;58(4):1018-1022
35. Howson JM, Walker NM, Smyth DJ, et al. Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun 2009;10(Suppl 1):S74-84
36. Qu HQ, Bradfield JP, Grant SF, et al. Remapping the type I diabetes association of the CTLA4 locus. Genes Immun 2009;10(Suppl 1):S27-32
37. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423(6939):506-511
38. Wei Z, Wang K, Qu HQ, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet 2009;5(10):e1000678
39. Eckenrode SE, Ruan Q, Yang P, et al. Gene expression profiles define a key checkpoint for type 1 diabetes in NOD mice. Diabetes 2004;53(2):366-375
40. Kodama K, Butte AJ, Creusot RJ, et al. Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Clin Immunol 2008;129(2):195-201
41. Mi QS, Meagher C, Delovitch TL. CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes. Novartis Found Symp 2003;252:146-160
42. Irie J, Reck B, Wu Y, et al. Genome-wide microarray expression analysis of CD4+ T Cells from nonobese diabetic congenic mice identifies Cd55 (Daf1) and Acadl as candidate genes for type 1 diabetes. J Immunol 2008;180(2):1071-1079
43. Chen Z, Herman AE, Matos M, et al. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005;202(10):1387-1397
44. Zucchelli S, Holler P, Yamagata T, et al. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 2005;22(3):385-396
45. Matos M, Park R, Mathis D, et al. Progression to islet destruction in a cyclophosphamide-induced transgenic model: a microarray overview. Diabetes 2004;53(9):2310-2321
46. Ortis F, Naamane N, Flamez D, et al. Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes 2010;59(2):358-374
47. Ortis F, Pirot P, Naamane N, et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008;51(7):1213-1225
48. Flamez D, Roland I, Berton A, et al. A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gamma as a pancreatic beta cell-specific biomarker. Diabetologia 2010;53(7):1372-1383
49. Kutlu B, Burdick D, Baxter D, et al. Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics 2009;2:3
50. Kutlu B, Cardozo AK, Darville MI, et al. Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells. Diabetes 2003;52(11):2701-2719
51. Eizirik DL, Kutlu B, Rasschaert J, et al. Use of microarray analysis to unveil transcription factor and gene networks contributing to Beta cell dysfunction and apoptosis. Ann NY Acad Sci 2003;1005:55-74
52. Collins CD, Purohit S, Podolsky RH, et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol 2006;45(5):258-267
53. Elo LL, Mykkanen J, Nikula T, et al. Early suppression of immune response pathways characterizes children with prediabetes in genome-wide gene expression profiling. J Autoimmun 2010;35(1):70-76
54. Kaizer EC, Glaser CL, Chaussabel D, et al. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007;92(9):3705-3711
55. Reynier F, Pachot A, Paye M, et al. Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun 2010;11(3):269-278
56. Wang X, Jia S, Geoffrey R, et al. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008;180(3):1929-1937
57. nPOD program. Available from: http://www.jdrfnpod.org/index.php [Last accessed July 9 2010]
58. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008;65(4):395-407
59. Beyan H, Drexhage RC, van der Heul NL, et al. Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins. Diabetes 2010;59(7):1751-1755
60. The TEDDY Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007;8(5):286-298
61. Randall SA, McKay MJ, Molloy MP. Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics 2010;10(10):2050-2056
62. Borges CR, Rehder DS, Jarvis JW, et al. Full-length characterization of proteins in human populations. Clin Chem 2010;56(2):202-211
63. Zhi W, Purohit S, Carey C, et al. Proteomic technologies for the discovery of type 1 diabetes biomarkers. J Diabetes Sci Technol 2010;4(4):993-1003
64. Wang H, Hanash S. Intact-protein based sample preparation strategies for proteome analysis in combination with mass spectrometry. Mass Spectrom Rev 2005;24(3):413-426
65. Zhang X, Fang A, Riley CP, et al. Multi-dimensional liquid chromatography in proteomics - a review. Anal Chim Acta 2010;664(2):101-113
66. Kakisaka T, Kondo T, Okano T, et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852(1-2):257-267
67. Okano T, Kondo T, Kakisaka T, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006;6(13):3938-3948
68. Immler D, Greven S, Reinemer P. Targeted proteomics in biomarker validation: detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics 2006;6(10):2947-2958
69. Wang H, Hanash S. Multi-dimensional liquid phase based separations in proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2003;787(1):11-18
70. Chatterjee NK, Haley TM, Nejman C. Functional alterations in pancreatic beta cells as a factor in virus-induced hyperglycemia in mice. J Biol Chem 1985;260(23):12786-12791
71. Waanders LF, Chwalek K, Monetti M, et al. Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA 2009;106(45):18902-18907
72. Sparre T, Bergholdt R, Nerup J, et al. Application of genomics and proteomics in type 1 diabetes pathogenesis research. Expert Rev Mol Diagn 2003;3(6):743-757
73. Sparre T, Larsen MR, Heding PE, et al. Unraveling the pathogenesis of type 1 diabetes with proteomics: present and future directions. Mol Cell Proteomics 2005;4(4):441-457
74. Suss C, Solimena M. Proteomic profiling of beta-cells using a classical approach-two-dimensional gel electrophoresis. Exp Clin Endocrinol Diabetes 2008;116(Suppl 1):S13-20
75. Winer S, Tsui H, Lau A, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003;9(2):198-205
76. Hu L, Evers S, Lu ZH, et al. Two-dimensional protein database of human pancreas. Electrophoresis 2004;25(3):512-518
77. Hohmeier HE, Newgard CB. Cell lines derived from pancreatic islets. Mol Cell Endocrinol 2004;228(1-2):121-128
78. Rossini AA, Handler ES, Mordes JP, et al. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice - Caveat emptor. Clin Immunol Immunopathol 1995;74(1):2-9
79. Brunner Y, Schvartz D, Priego-Capote F, et al. Glucotoxicity and pancreatic proteomics. J Proteomics 2009;71(6):576-591
80. Sundsten T, Ortsater H. Proteomics in diabetes research. Mol Cell Endocrinol 2009;297(1-2):93-103
81. Hedman M, Ludvigsson J, Faresjo MK. Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J Interferon Cytokine Res 2006;26(4):207-213
82. Hussain MJ, Peakman M, Gallati H, et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996;39(1):60-69
83. Karlsson MG, Lawesson SS, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 2000;43(6):742-749
84. Karlsson Faresjo MG, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005;61(2):173-179
85. Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004;59(5):517-526
86. Ryden A, Stechova K, Durilova M, et al. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab Res Rev 2009;25(4):335-343
87. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7(6):443-453
88. Fujio K, Okamura T, Yamamoto K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol 2010;105:99-130
89. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28(4):546-558
90. Metz TO, Qian WJ, Jacobs JM, et al. Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset. J Proteome Res 2008;7(2):698-707
91. Purohit S, Podolsky R, Schatz D, et al. Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics 2006;6(24):6405-6415
92. Overgaard AJ, Hansen HG, Lajer M, et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci 2010;8:4
93. Cooper JD, Walker NM, Smyth DJ, et al. Follow-up of 1715 SNPs from the Wellcome Trust Case Control Consortium genome-wide association study in type I diabetes families. Genes Immun 2009;10(Suppl 1):S85-94
94. Wallace C, Smyth DJ, Maisuria-Armer M, et al. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet 2010;42(1):68-71
95. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005;129(4):1187-1197
96. Coute Y, Brunner Y, Schvartz D, et al. Early activation of the fatty acid metabolism pathway by chronic high glucose exposure in rat insulin secretory beta-cells. Proteomics 2010;10(1):59-71
97. Choi JS, Cho YK, Yoon SH, et al. Proteomic analysis of porcine pancreas development. BMB Rep 2009;42(10):661-666
98. Alberti A, Karamessinis P, Peroulis M, et al. ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2009;297(3):E812-21
99. Kakisaka T, Kondo T, Okano T, et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852(1-2):257-267
100. Okano T, Kondo T, Kakisaka T, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006;6(13):3938-3948
101. Immler D, Greven S, Reinemer P. Targeted proteomics in biomarker validation: detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics 2006;6(10):2947-2958
102. Wang H, Hanash S. Multi-dimensional liquid phase based separations in proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2003;787(1):11-18
103. Chatterjee NK, Haley TM, Nejman C. Functional alterations in pancreatic beta cells as a factor in virus-induced hyperglycemia in mice. J Biol Chem 1985;260(23):12786-12791
104. Waanders LF, Chwalek K, Monetti M, et al. Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA 2009;106(45):18902-18907
105. Sparre T, Bergholdt R, Nerup J, et al. Application of genomics and proteomics in type 1 diabetes pathogenesis research. Expert Rev Mol Diagn 2003;3(6):743-757
106. Sparre T, Larsen MR, Heding PE, et al. Unraveling the pathogenesis of type 1 diabetes with proteomics: present and future directions. Mol Cell Proteomics 2005;4(4):441-457
107. Suss C, Solimena M. Proteomic profiling of beta-cells using a classical approach-two-dimensional gel electrophoresis. Exp Clin Endocrinol Diabetes 2008;116(Suppl 1):S13-20
108. Winer S, Tsui H, Lau A, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003;9(2):198-205
109. Hu L, Evers S, Lu ZH, et al. Two-dimensional protein database of human pancreas. Electrophoresis 2004;25(3):512-518
110. Hohmeier HE, Newgard CB. Cell lines derived from pancreatic islets. Mol Cell Endocrinol 2004;228(1-2):121-128
111. Rossini AA, Handler ES, Mordes JP, et al. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice - Caveat emptor. Clin Immunol Immunopathol 1995;74(1):2-9
112. Brunner Y, Schvartz D, Priego-Capote F, et al. Glucotoxicity and pancreatic proteomics. J Proteomics 2009;71(6):576-591
113. Sundsten T, Ortsater H. Proteomics in diabetes research. Mol Cell Endocrinol 2009;297(1-2):93-103
114. Hedman M, Ludvigsson J, Faresjo MK. Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J Interferon Cytokine Res 2006;26(4):207-213
115. Hussain MJ, Peakman M, Gallati H, et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996;39(1):60-69
116. Karlsson MG, Lawesson SS, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 2000;43(6):742-749
117. Karlsson Faresjo MG, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005;61(2):173-179
118. Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004;59(5):517-526
119. Ryden A, Stechova K, Durilova M, et al. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab Res Rev 2009;25(4):335-343
120. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7(6):443-453
121. Fujio K, Okamura T, Yamamoto K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol 2010;105:99-130
122. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28(4):546-558
123. Metz TO, Qian WJ, Jacobs JM, et al. Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset. J Proteome Res 2008;7(2):698-707
124. Purohit S, Podolsky R, Schatz D, et al. Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics 2006;6(24):6405-6415
125. Overgaard AJ, Hansen HG, Lajer M, et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci 2010;8:4
126. Cooper JD, Walker NM, Smyth DJ, et al. Follow-up of 1715 SNPs from the Wellcome Trust Case Control Consortium genome-wide association study in type I diabetes families. Genes Immun 2009;10(Suppl 1):S85-94
127. Wallace C, Smyth DJ, Maisuria-Armer M, et al. The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet 2010;42(1):68-71
128. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005;129(4):1187-1197
129. Coute Y, Brunner Y, Schvartz D, et al. Early activation of the fatty acid metabolism pathway by chronic high glucose exposure in rat insulin secretory beta-cells. Proteomics 2010;10(1):59-71
130. Choi JS, Cho YK, Yoon SH, et al. Proteomic analysis of porcine pancreas development. BMB Rep 2009;42(10):661-666
131. Alberti A, Karamessinis P, Peroulis M, et al. ERp46 is reduced by high glucose and regulates insulin content in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2009;297(3):E812-21
132. Song G, Cui Y, Zhong N, et al. Proteomic characterisation of pancreatic islet beta-cells stimulated with pancreatic carcinoma cell conditioned medium. J Clin Pathol 2009;62(9):802-807
133. Nyblom HK, Bugliani M, Fung E, et al. Apoptotic, regenerative, and immune-related signaling in human islets from type 2 diabetes individuals. J Proteome Res 2009;8(12):5650-5656
134. Antwi K, Hanavan PD, Myers CE, et al. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines. Mol Immunol 2009;46(15):2931-2937
135. Lee HS, Jeong J, Lee KJ. Characterization of vesicles secreted from insulinoma NIT-1 cells. J Proteome Res 2009;8(6):2851-2862
136. Jin J, Park J, Kim K, et al. Detection of differential proteomes of human beta-cells during islet-like differentiation using iTRAQ labeling. J Proteome Res 2009;8(3):1393-1403
137. Jeffrey KD, Alejandro EU, Luciani DS, et al. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci USA 2008;105(24):8452-8457